ArticleClinical and experimental immunology2016
Pulmonary sarcoidosis is associated with high-level inducible co-stimulator (ICOS) expression on lung regulatory T cells--possible implications for the ICOS/ICOS-ligand axis in disease course and resolution.
Article in Clinical and experimental immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis.Clinical and experimental immunology · 2020Trial
- Phenotypes and Endotypes in Sarcoidosis: Unraveling Prognosis and Disease Course.Biomedicines · 2025Review
- Review
- Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis.Journal of clinical medicine · 2023Review
- Th17/Treg Imbalance: Implications in Lung Inflammatory Diseases.International journal of molecular sciences · 2023Review
- Immune-mediated lung diseases: A narrative review.Frontiers in medicine · 2023Review
- Immune mechanisms in fibrotic pulmonary sarcoidosis.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Activation Markers on B and T Cells and Immune Checkpoints in Autoimmune Rheumatic Diseases.International journal of molecular sciences · 2022Review
- Increased Levels of ICOS and ICOSL Are Associated to Pulmonary Arterial Hypertension in Patients Affected by Connective Tissue Diseases.Diagnostics (Basel, Switzerland) · 2022Article
- Identification of key regulators in Sarcoidosis through multidimensional systems biological approach.Scientific reports · 2022Article
- Sarcoidosis and autoimmunity: In the depth of a complex relationship.Frontiers in medicine · 2022Review
- Key Players and Biomarkers of the Adaptive Immune System in the Pathogenesis of Sarcoidosis.International journal of molecular sciences · 2020Review
- Sarcoidosis exosomes stimulate monocytes to produce pro-inflammatory cytokines and CCL2.Scientific reports · 2020Article
- ICOSFrontiers in immunology · 2020Review
- Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis.Journal of biomedical science · 2019Review
- Regulatory T Cells in Respiratory Health and Diseases.Pulmonary medicine · 2019Review
- B cell subset alteration and the expression of tissue homing molecules in dengue infected patients.Journal of biomedical science · 2018Article
- Plasmacytoid dendritic cells in cutaneous sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2018Article
- Flow cytometric analysis of lymphocyte profiles in mediastinal lymphadenopathy of sarcoidosis.PloS one · 2018Article
- Mass Cytometry Identifies Distinct Lung CD4Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a granulomatous inflammatory disorder of unknown aetiology. The increased frequency of activated lung CD4(+) T cells with a T helper type 1 (Th1) cytokine profile in sarcoidosis patients is accompanied by a reduced proportion and/or impaired function of regulatory T cells (Tregs ). Here we evaluated the expression of the inducible co-stimulator (ICOS) on lung and blood CD4(+) T cell subsets in sarcoidosis patients with different prognosis, by flow cytometry. Samples from the deep airways were obtained by bronchoalveolar lavage (BAL). We show that Tregs from the inflamed lung of sarcoidosis patients were characterized by a unique ICOS(high) phenotype. High-level ICOS expression was restricted to Tregs from the inflamed lung and was absent in blood Tregs of sarcoidosis patients as well as in lung and blood Tregs of healthy volunteers. In addition, lung Tregs exhibited increased ICOS expression compared to sarcoid-specific lung effector T cells. Strikingly, ICOS expression on Tregs was in particularly high in the lungs of Löfgren's syndrome (LS) patients who present with acute disease which often resolves spontaneously. Moreover, blood monocytes from LS patients revealed increased ICOS-L levels compared to healthy donors. Sarcoidosis was associated with a shift towards a non-classical monocyte phenotype and the ICOS-L(high) phenotype was restricted to this particular monocyte subset. We propose a potential implication of the ICOS/ICOS-L immune-regulatory axis in disease activity and resolution and suggest to evaluate further the suitability of ICOS as biomarker for the prognosis of sarcoidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.